[
    [
        {
            "time": "2021-11-09",
            "original_text": "Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes",
            "features": {
                "keywords": [
                    "Bamlanivimab",
                    "COVID-19",
                    "Nursing Homes"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Lilly Completes Acquisition of Prevail Therapeutics",
            "features": {
                "keywords": [
                    "Lilly",
                    "Acquisition",
                    "Prevail Therapeutics"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly Completes Acquisition of Prevail Therapeutics",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal",
            "features": {
                "keywords": [
                    "FDA",
                    "MRK",
                    "AZN",
                    "JNJ",
                    "GSK",
                    "LLY",
                    "Antibody Deal"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa",
            "features": {
                "keywords": [
                    "Fluidigm",
                    "Saliva-Based",
                    "COVID",
                    "Test",
                    "Europe",
                    "China",
                    "Amarin",
                    "Vascepa"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]